SecurityCP / Canadian Pacific Railway Ltd. (13645T100)
IndustryRailroads, Line-Haul Operating
Common Stock Shares Outstanding146,100,000 shares (as of 2017-06-30)
Total Insiders27
Total Directors12
Total Officers14

Stock Insider Trading (from SEC Form 4)

Canadian Pacific Railway Ltd. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

CP / Canadian Pacific Railway Ltd. insiders include Johnson Robert Allen, Harrison E Hunter, TRAFTON GORDON T. II Pershing Square Capital Management, L.P., PS Management GP, LLC, Pitz Laird Joseph, MacDonald Ubavka Rebecca, Foran Mike, Velani Nadeem, ACKMAN WILLIAM A, Brooks John Kenneth, and Derry John E, Reardon Andrew Fitzpatrick, Clements James Dominic Luther, Fatt William R., Edwards Peter John, Creel Keith Edward, Ellis Jeffrey Jerom, PAULL MATTHEW H, Erceg Mark J, Wallace Mark Kenneth, DENHAM GILLIAN H, Courville Isabelle, Peverett Jane L, Redeker Michael John, Melman Anthony Ronald, Baird John Russell, .

Insider Roster

Insider Dir Off 10% Shares Owned
MacDonald Ubavka Rebecca Director
X
Baird John Russell Director
X
Reardon Andrew Fitzpatrick Director
X
Courville Isabelle Director
X
TRAFTON GORDON T. II Director
X
Fatt William R. Director
X
DENHAM GILLIAN H Director
X
Peverett Jane L Director
X
PAULL MATTHEW H Director
X
Brooks John Kenneth SVP & Chief Marketing Officer
X 1,587
Clements James Dominic Luther VP Planning & Transportation
X 1,921
Derry John E Vice-President Human Resources
X 242
Ellis Jeffrey Jerom Chief Legal Officer & Corp Sec
X 299
Johnson Robert Allen Executive VP Operations
X 97
Foran Mike VP Network Transportation
X 1,591
Creel Keith Edward President & CEO, Director
X X 2,087
Velani Nadeem VP and CFO
X 340
Redeker Michael John VP & Chief Information Officer
X 951
Edwards Peter John VP People
X 2,456
Pitz Laird Joseph VP & Chief Risk Officer
X
Wallace Mark Kenneth VP Corp Affrs & Chief of Staff
X
Harrison E Hunter Chief Executive Officer, Director
X X
Pershing Square Capital Management, L.P.
PS Management GP, LLC
ACKMAN WILLIAM A
Erceg Mark J EVP & CFO
X
Melman Anthony Ronald Director
X

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Tran
Date
Form Insider Code 10b-5 Direct Share
Price
Shares
Changed
Remaining
Shares
Post Value
2017-06-30 4 Redeker Michael John By ESPP J I 162.18 15 951
2017-06-30 4 Velani Nadeem By ESPP J I 162.18 13 340
2017-06-30 4 Creel Keith Edward By ESPP J I 159.63 47 2,087
2017-06-30 4 Foran Mike By ESPP J I 162.18 7 1,591
2017-06-30 4 Johnson Robert Allen By ESPP J I 159.63 27 97
2017-06-30 4 Ellis Jeffrey Jerom By ESPP J I 162.16 13 299
2017-06-30 4 Derry John E By ESPP J I 162.16 10 242
2017-06-30 4 Clements James Dominic Luther By ESPP J I 162.12 10 1,921
2017-06-30 4 Brooks John Kenneth By ESPP J I 159.63 15 1,587
2017-05-31 4 Redeker Michael John By ESPP J I 158.86 15 936
2017-05-31 4 Foran Mike By ESPP J I 158.86 8 1,584
2017-05-31 4 Velani Nadeem By ESPP J I 158.88 13 327
2017-05-31 4 Derry John E By ESPP J I 158.81 9 232
2017-05-31 4 Clements James Dominic Luther By ESPP J I 158.90 10 1,911
2017-05-31 4 Ellis Jeffrey Jerom By ESPP J I 158.83 13 286
2017-06-01 4 Brooks John Kenneth By ESPP J I 159.79 14 1,572
2017-06-01 4 Creel Keith Edward By ESPP J I 159.79 46 2,040
2017-06-01 4 Johnson Robert Allen By ESPP J I 159.79 28 70
2017-05-02 4 Redeker Michael John By ESPP J I 153.18 17 921
2017-05-02 4 Velani Nadeem By ESPP J I 153.16 14 314
2017-05-02 4 Foran Mike By ESPP J I 153.22 19 1,576
2017-05-02 4 Johnson Robert Allen By ESPP J I 154.67 28 42
2017-05-02 4 Edwards Peter John By ESPP J I 153.27 23 2,456
2017-05-02 4 Ellis Jeffrey Jerom By ESPP J I 153.24 14 273
2017-05-02 4 Clements James Dominic Luther By ESPP J I 153.31 14 1,901
2017-05-02 4 Creel Keith Edward By ESPP J I 154.72 45 1,994
2017-04-28 4 Creel Keith Edward By ESPP J I 154.63 3 1,949
2017-05-02 4 Derry John E By ESPP J I 153.25 10 223
2017-05-02 4 Brooks John Kenneth By ESPP J I 154.72 15 1,558
2017-04-28 4 Brooks John Kenneth By ESPP J I 154.63 3 1,543
2017-03-31 4 Redeker Michael John By ESPP J I 147.98 17 904
2017-03-31 4 Foran Mike By ESPP J I 148.02 7 1,557
2017-03-31 4 Brooks John Kenneth By ESPP J I 146.39 14 1,540
2017-03-31 4 Creel Keith Edward By ESPP J I 146.39 44 1,946
2017-03-31 4 Derry John E By ESPP J I 148.06 10 213
2017-03-31 4 Johnson Robert Allen By ESPP J I 146.39 14 14
2017-03-31 4 Edwards Peter John By ESPP J I 148.06 19 2,433
2017-03-31 4 Clements James Dominic Luther By ESPP J I 148.06 11 1,887
2017-03-31 4 Velani Nadeem By ESPP J I 148.02 15 300
2017-03-31 4 Ellis Jeffrey Jerom By ESPP J I 148.08 14 259
2017-03-21 4 Edwards Peter John F D 146.79 -4,503 6,830
2017-03-21 4 Edwards Peter John M D 37.28 10,300 11,333
2017-03-01 4 Clements James Dominic Luther By ESPP J I 146.37 11 1,876
2017-03-01 4 Velani Nadeem By ESPP J I 146.52 13 285
2017-03-01 4 Redeker Michael John By ESPP J I 146.50 16 887
2017-03-01 4 Creel Keith Edward By ESPP J I 149.53 42 1,902
2017-03-01 4 Derry John E By ESPP J I 146.39 10 203
2017-03-01 4 Edwards Peter John By ESPP J I 146.49 18 2,414
2017-03-01 4 Ellis Jeffrey Jerom By ESPP J I 146.49 14 245
2017-03-01 4 Brooks John Kenneth By ESPP J I 149.53 12 1,526
2017-03-01 4 Foran Mike By ESPP J I 146.50 8 1,550
2017-02-03 4 Creel Keith Edward By ESPP J I 151.41 3 1,860
2017-02-03 4 Edwards Peter John By ESPP J I 150.02 6 2,396
2017-02-03 4 Redeker Michael John By ESPP J I 150.02 2 871
2017-02-01 4 Derry John E By ESPP J I 156.05 15 193
2017-02-01 4 Redeker Michael John By ESPP J I 155.81 24 869
2017-02-01 4 Ellis Jeffrey Jerom By ESPP J I 156.08 20 231
2017-02-01 4 Creel Keith Edward By ESPP J I 155.60 41 1,857
2017-02-01 4 Edwards Peter John By ESPP J I 156.09 27 2,390
2017-02-01 4 Velani Nadeem By ESPP J I 155.83 19 272
2017-01-26 4 Wallace Mark Kenneth By ESPP S I 154.36 -577 45 6,946
2017-01-24 4 Wallace Mark Kenneth S D 152.44 -2,580 0
2017-01-24 4 Wallace Mark Kenneth M D 122.73 2,580 2,580
2017-01-24 4 Wallace Mark Kenneth S D 152.46 -1,330 0
2017-01-24 4 Wallace Mark Kenneth M D 116.80 1,330 1,330
2017-01-23 4 Wallace Mark Kenneth S D 150.12 -3,580 0
2017-01-23 4 Wallace Mark Kenneth M D 94.08 3,580 3,580
2017-01-23 4 Wallace Mark Kenneth S D 150.23 -4,500 0
2017-01-23 4 Wallace Mark Kenneth M D 86.64 4,500 4,500
2017-01-20 4 Harrison E Hunter Jeannie D. Harrison Revocable Trust S I 150.82 -24,666 0
2017-01-20 4 Harrison E Hunter E. Hunter Harrison Revocable Trust S I 150.8066 -153,951 0
2017-01-03 4 Creel Keith Edward By ESPP J I 143.14 44 1,904
2017-01-03 4 Derry John E By ESPP J I 145.58 10 178
2017-01-03 4 Redeker Michael John By ESPP J I 145.67 16 845
2017-01-03 4 Ellis Jeffrey Jerom By ESPP J I 145.64 14 211
2017-01-03 4 Edwards Peter John By ESPP J I 145.63 19 2,363
2017-01-03 4 Wallace Mark Kenneth By ESPP J I 145.72 15 622
2017-01-03 4 Velani Nadeem By ESPP J I 145.68 13 253
2016-12-23 4 MacDonald Ubavka Rebecca S D 143.65 -3,900 0
2016-11-30 4 Derry John E By ESPP J I 150.51 9 168
2016-11-30 4 Redeker Michael John By ESPP J I 150.52 16 829
2016-11-30 4 Ellis Jeffrey Jerom By ESPP J I 150.57 13 197
2016-11-30 4 Creel Keith Edward By ESPP J I 149.61 64 1,772
2016-11-30 4 Edwards Peter John By ESPP J I 150.54 19 2,344
2016-11-30 4 Wallace Mark Kenneth By ESPP J I 150.57 15 607
2016-11-30 4 Velani Nadeem By ESPP J I 150.57 12 240
2016-11-23 4 Edwards Peter John S D 149.60 -15,300 1,033 154,537
2016-11-23 4 Edwards Peter John M D 41.37 15,300 16,333
2016-11-02 4 Derry John E By ESPP J I 145.24 10 159
2016-11-02 4 Redeker Michael John By ESPP J I 145.43 19 813
2016-11-02 4 Ellis Jeffrey Jerom By ESPP J I 145.26 14 184
2016-11-02 4 Creel Keith Edward By ESPP J I 145.10 44 1,708
2016-10-31 4 Creel Keith Edward By ESPP J I 142.75 3 1,664
2016-11-02 4 Edwards Peter John By ESPP J I 145.16 24 2,325
2016-11-02 4 Wallace Mark Kenneth By ESPP J I 145.78 16 592
2016-11-02 4 Velani Nadeem By ESPP J I 145.43 12 228
2016-09-30 4 Redeker Michael John By ESPP J I 148.04 24 794
2016-09-30 4 Ellis Jeffrey Jerom By ESPP J I 148.04 28 170
2016-09-30 4 Creel Keith Edward By ESPP J I 146.88 21 1,661
2016-09-30 4 Edwards Peter John By ESPP J I 148.04 28 2,301
2016-09-30 4 Wallace Mark Kenneth By ESPP J I 148.04 22 576
2016-09-30 4 Velani Nadeem By ESPP J I 148.04 13 216
2016-08-31 4 Erceg Mark J By ESPP J I 150.96 21 371
2016-08-31 4 Redeker Michael John By ESPP J I 151.06 16 770
2016-08-31 4 Ellis Jeffrey Jerom By ESPP J I 151.03 21 142
2016-08-31 4 Creel Keith Edward By ESPP J I 153.34 42 1,640
2016-08-09 4 Creel Keith Edward By ESPP J I 142.78 25 1,598
2016-08-31 4 Edwards Peter John By ESPP J I 151.03 19 2,273
2016-08-31 4 Wallace Mark Kenneth By ESPP J I 151.06 15 554
2016-08-03 4 Pershing Square Capital Management, L.P. See footnotes S I 141.68 -9,840,890 0
2016-08-02 4 Erceg Mark J By ESPP J I 147.43 23 350
2016-08-02 4 Redeker Michael John By ESPP J I 147.46 19 754
2016-08-02 4 Ellis Jeffrey Jerom By ESPP J I 147.46 22 121
2016-08-02 4 Creel Keith Edward By ESPP J I 148.58 21 1,573
2016-08-02 4 Edwards Peter John By ESPP J I 147.79 25 2,254
2016-08-02 4 Wallace Mark Kenneth By ESPP J I 147.43 16 539
2016-06-30 4 Erceg Mark J By ESPP J I 121.87 27 327
2016-06-30 4 Redeker Michael John By ESPP J I 121.88 20 735
2016-06-30 4 Ellis Jeffrey Jerom By ESPP J I 121.87 26 99
2016-06-30 4 Creel Keith Edward By ESPP J I 121.92 26 1,552
2016-06-30 4 Edwards Peter John By ESPP J I 121.87 23 2,229
2016-06-30 4 Wallace Mark Kenneth By ESPP J I 121.89 19 523
2016-06-01 4 Edwards Peter John By ESPP J I 128.69 22 2,206
2016-06-02 4 Creel Keith Edward By ESPP J I 129.00 74 1,526
2016-05-05 4 Creel Keith Edward By ESPP J I 144.25 2 1,452
2016-06-01 4 Ellis Jeffrey Jerom By ESPP J I 128.68 24 73
2016-06-01 4 Redeker Michael John By ESPP J I 128.68 20 715
2016-06-01 4 Wallace Mark Kenneth By ESPP J I 128.71 17 504
2016-06-01 4 Erceg Mark J By ESPP J I 144.05 24 300
2016-03-24 4 Erceg Mark J By ESPP J I 129.25 3 276
2016-03-10 4 Erceg Mark J By ESPP J I 130.22 4 273
2016-02-25 4 Erceg Mark J By ESPP J I 130.22 4 269
2016-02-11 4 Erceg Mark J By ESPP J I 126.77 4 265
2016-01-28 4 Erceg Mark J By ESPP J I 126.77 4 261
2016-01-14 4 Erceg Mark J By ESPP J I 125.54 4 257
2016-05-02 4 Creel Keith Edward By ESPP J I 145.44 20 1,450
2016-05-02 4 Edwards Peter John By ESPP J I 144.05 22 2,184
2016-05-02 4 Ellis Jeffrey Jerom By ESPP J I 143.98 19 49
2016-05-02 4 Erceg Mark J By ESPP J I 144.05 24 253
2016-05-02 4 Redeker Michael John By ESPP J I 144.05 17 695
2016-05-02 4 Wallace Mark Kenneth By ESPP J I 144.05 13 487
2016-04-26 4 PAULL MATTHEW H P D 143.89 1,000 1,000 143,890
2016-04-25 4 Edwards Peter John P D 147.00 1 1,033 151,851
2016-04-22 4 Pershing Square Capital Management, L.P. See footnotes S I 148.25 -4,100,000 9,840,890 1,458,911,942
2016-03-31 4 Creel Keith Edward By ESPP J I 128.55 71 6,638
2016-03-02 4 Creel Keith Edward By ESPP J I 121.88 50 6,638
2016-02-02 4 Creel Keith Edward By ESPP J I 117.73 27 6,638
2016-01-04 4 Creel Keith Edward By ESPP J I 128.41 24 6,638
2015-12-31 4 Creel Keith Edward By ESPP J I 127.56 48 6,638
2016-04-01 4 Edwards Peter John By ESPP J I 130.00 9 10,661
2016-03-31 4 Edwards Peter John By ESPP J I 130.98 18 10,661
2016-03-02 4 Edwards Peter John By ESPP J I 127.52 18 10,661
2016-02-02 4 Edwards Peter John By ESPP J I 126.27 23 10,661
2015-12-31 4 Edwards Peter John By ESPP J I 137.18 17 10,661
2016-04-01 4 Ellis Jeffrey Jerom By ESPP J I 130.00 10 50
2016-03-31 4 Ellis Jeffrey Jerom By ESPP J I 130.98 20 50
2016-04-01 4 Erceg Mark J By ESPP J I 130.00 10 984
2016-03-31 4 Erceg Mark J By ESPP J I 130.98 19 984
2016-03-02 4 Erceg Mark J By ESPP J I 127.52 20 984
2016-02-02 4 Erceg Mark J By ESPP J I 126.27 24 984
2015-12-31 4 Erceg Mark J By ESPP J I 137.18 26 984
2016-04-01 4 Redeker Michael John By ESPP J I 130.00 8 3,260
2016-03-31 4 Redeker Michael John By ESPP J I 130.98 16 3,260
2016-03-02 4 Redeker Michael John By ESPP J I 127.52 16 3,260
2016-02-02 4 Redeker Michael John By ESPP J I 126.27 18 3,260
2015-12-31 4 Redeker Michael John By ESPP J I 137.18 15 3,260
2016-04-01 4 Wallace Mark Kenneth By ESPP J I 130.00 6 2,273
2016-03-31 4 Wallace Mark Kenneth By ESPP J I 130.98 12 2,273
2016-03-02 4 Wallace Mark Kenneth By ESPP J I 127.52 12 2,273
2016-02-02 4 Wallace Mark Kenneth By ESPP J I 126.27 13 2,273
2015-12-31 4 Wallace Mark Kenneth By ESPP J I 137.18 11 2,273
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...